Bagsværd, Denmark, November 16, 2026 – Novo Nordisk A/S has officially launched a share repurchase program aimed at buying back up to DKK 15 billion worth of its shares over the next year. This initiative, which began on May 6, 2026, is part of a broader strategy to enhance shareholder value and reflects the company's strong financial position.

This share repurchase program is significant, as it underscores Novo Nordisk's commitment to returning capital to its shareholders while also signaling confidence in its ongoing business performance. The program will run for a 12-month period, starting from February 4, 2026, and aims to repurchase B shares for an amount up to DKK 11.2 billion.

Background

Novo Nordisk A/S, classified under the SIC code 2834 for Pharmaceutical Preparations, is a global healthcare company that specializes in diabetes care and other chronic diseases. The company is publicly traded on the New York Stock Exchange under the ticker symbol NVO and also on the OTC market as NONOF. With a strong presence in the pharmaceutical industry, Novo Nordisk has consistently focused on innovation and expanding access to its treatments.

What the Filing Says

The recent filing states, "On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the 'Safe Harbour Rules')." The company has already repurchased a total of 43,734,179 B shares at an average price of DKK 277.08 per share, amounting to a transaction value of DKK 12.12 billion as of November 13, 2026.

Impact

This share repurchase program could have significant implications for investors and the broader pharmaceutical industry. By committing to buy back shares, Novo Nordisk is likely to enhance its stock value, benefiting existing shareholders. Additionally, this move may prompt competitors in the pharmaceutical sector to reconsider their own capital allocation strategies, potentially leading to similar initiatives aimed at boosting shareholder returns.

What's Next

As the share repurchase program progresses, further updates on the transactions will be published on Novo Nordisk's official website. The filing does not specify any additional upcoming actions or events related to this program.

For more information about Novo Nordisk and its ongoing initiatives, visit novonordisk.com.